Verve Therapeutics (VERV) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free VERV Stock Alerts $6.23 0.00 (0.00%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 7:02 PM | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Andrew D. Ashe Acquires 76,000 SharesVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Andrew D. Ashe acquired 76,000 shares of Verve Therapeutics stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average price of $6.26 per share, with a total value of $475,760.00. Following the purchase, the insider now directly owns 342,509 shares of the company's stock, valued at $2,144,106.34. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.May 13 at 1:54 AM | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 13 at 1:14 AM | americanbankingnews.comWilliam Blair Weighs in on Verve Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VERV)May 13 at 1:14 AM | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) to Post Q2 2024 Earnings of ($0.63) Per Share, HC Wainwright ForecastsMay 12, 2024 | investorplace.com3 Underappreciated Stocks That Could 10x in 10 YearsMay 12, 2024 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Verve Therapeutics (NASDAQ:VERV)May 11, 2024 | finance.yahoo.comVerve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong FinancialsMay 10, 2024 | finance.yahoo.comAnalysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This WeekMay 10, 2024 | americanbankingnews.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3% on Earnings BeatMay 9, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)May 9, 2024 | markets.businessinsider.comBuy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth PotentialMay 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Rating Reiterated by HC WainwrightHC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Verve Therapeutics in a research report on Thursday.May 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Releases Earnings Results, Beats Expectations By $0.11 EPSVerve Therapeutics (NASDAQ:VERV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.11. The firm had revenue of $5.70 million for the quarter, compared to analysts' expectations of $2.11 million. Verve Therapeutics had a negative net margin of 1,701.70% and a negative return on equity of 39.33%. The company's revenue was up 305.6% compared to the same quarter last year.May 9, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 6.3% Following Strong EarningsVerve Therapeutics (NASDAQ:VERV) Trading 6.3% Higher on Better-Than-Expected EarningsMay 9, 2024 | finance.yahoo.comVerve Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics Amid Progress and Promising PipelineMay 8, 2024 | msn.comVerve Therapeutics GAAP EPS of -$0.59 beats by $0.12, revenue of $5.7M beats by $3.45MMay 8, 2024 | investorplace.comVERV Stock Earnings: Verve Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | finance.yahoo.comVerve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comVerve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102May 3, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Trading Up 7.8%Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7.8%May 3, 2024 | globenewswire.comVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $5.93Verve Therapeutics (NASDAQ:VERV) Hits New 12-Month Low at $5.93April 25, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Hits New 52-Week Low at $6.05Verve Therapeutics (NASDAQ:VERV) Reaches New 52-Week Low at $6.05April 21, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Grows Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)Sumitomo Mitsui Trust Holdings Inc. boosted its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 11.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,397,604 shares of the company's stock after buApril 20, 2024 | marketbeat.comFederated Hermes Inc. Purchases 1,448,003 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)Federated Hermes Inc. lifted its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 57.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,980,372 shares of the company's stock after buying an addiApril 18, 2024 | wsj.comGV’s Newest Life Sciences General Partner Pursues Precision TreatmentsApril 18, 2024 | msn.comVerve Therapeutics (VERV) Price Target Decreased by 37.88% to 32.77April 17, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Down 2.9%Verve Therapeutics (NASDAQ:VERV) Shares Down 2.9%April 15, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Sets New 1-Year Low at $7.26Verve Therapeutics (NASDAQ:VERV) Reaches New 12-Month Low at $7.26April 11, 2024 | benzinga.comTop 3 Health Care Stocks Which Could Rescue Your Portfolio This QuarterApril 9, 2024 | markets.businessinsider.comBuy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated RecoveryApril 9, 2024 | msn.comA Bold Gene-Editing Solution Began Testing—Then Hit the Strangest TwistApril 8, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Coverage Initiated at HC WainwrightHC Wainwright initiated coverage on shares of Verve Therapeutics in a research report on Monday. They issued a "buy" rating and a $15.00 price objective for the company.April 8, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Stock Position Raised by Vanguard Group Inc.Vanguard Group Inc. lifted its position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 18.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,832,968 shares of the company's stock after buying an additional 741,April 6, 2024 | fool.comAfter a Serious Setback, Is Verve Therapeutics a Buy?April 4, 2024 | marketbeat.comVerve Therapeutics (NASDAQ:VERV) Stock Price Up 4.8%Verve Therapeutics (NASDAQ:VERV) Shares Up 4.8%April 4, 2024 | insidertrades.comJoan Nickerson Sells 1,514 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) StockApril 3, 2024 | msn.comGene Editing Experiment Halted as Patient Gets Weird Side EffectsApril 3, 2024 | marketbeat.comVerve Therapeutics, Inc. (NASDAQ:VERV) Insider Joan Nickerson Sells 1,514 SharesVerve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) insider Joan Nickerson sold 1,514 shares of the business's stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $8.24, for a total value of $12,475.36. Following the completion of the sale, the insider now owns 8,659 shares in the company, valued at $71,350.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.April 3, 2024 | seekingalpha.comVerve Therapeutics: An Update On Human CRISPRApril 3, 2024 | seekingalpha.comVerve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment PauseApril 2, 2024 | msn.comVerve Therapeutics pauses enrollment of patients in trial for its gene therapy to treat high cholesterol after severe side effectApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verve Therapeutics with Strategic Focus on Promising VERVE-102 ProgramApril 2, 2024 | bizjournals.comVerve’s stock tumbles as biotech pauses gene editing trial over safety concernsApril 2, 2024 | marketwatch.comVerve Therapeutics Pauses Enrollment in Trial of Gene Editing Medicine After Serious Adverse EventApril 2, 2024 | markets.businessinsider.comVerve Therapeutics To Halt Enrollment In Heart-1 Phase 1b Trial Of VERVE-101; Stock FallsApril 2, 2024 | msn.comVerve drops after pausing enrollments in trial for lead assetApril 2, 2024 | msn.comVerve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address This is the best new way to score with AI (Ad)If you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open. Click now for the best way into the newest AI projects VERV Media Mentions By Week VERV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERV News Sentiment▼0.580.55▲Average Medical News Sentiment VERV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERV Articles This Week▼254▲VERV Articles Average Week Get Verve Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Astria Therapeutics News Today KalVista Pharmaceuticals News Today Applied Therapeutics News Today Y-mAbs Therapeutics News Today Travere Therapeutics News Today Aerovate Therapeutics News Today Arbutus Biopharma News Today IGM Biosciences News Today Larimar Therapeutics News Today Oculis News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERV) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
